Medical Information Only: This medication is not sold on this site. The information provided is for reference purposes only. Please consult your local physician or pharmacist for treatment.

ProstaScint (Cytogen Corp): Full Drug Profile

Medically reviewed by Min Clinic Staff | Updated: January 2026

ProstaScint (Cytogen Corp) - General Information

Murine IgG1 monoclonal antibody 7E11-C5.3 antibody conjugated to linker chelator peptide group for indium attachment

 

Pharmacology of ProstaScint (Cytogen Corp)

Binds to the prostate-specific membrane antigen, which is a cell surface protein generally overexpressed in prostate tissues and prostate cancers. The radioactive Indium 111, which is covalently attached to the antibody, allows radiodiagnostic detection of PSMA expressing cells and tumors

 

Additional information about ProstaScint (Cytogen Corp)

ProstaScint (Cytogen Corp) Indication: For diagnosis of prostate cancer and detection of intra-pelvic metastases Mechanism Of Action: Binds selectively to cell-surface prostate-specific membrane antigen (PSMA) expressed on prostate tissues and tumors. Drug Interactions: Not Available Food Interactions: Not Available Generic Name: Capromab Synonyms: ProstaScint; Capromab pendetide Drug Category: Imaging Agents Drug Type: Biotech; Approved Other Brand Names containing Capromab: ProstaScint (Cytogen Corp); Absorption: Not Available Toxicity (Overdose): Not Available Protein Binding: Not Available Biotransformation: Most likely removed by opsonization via the reticuloendothelial system or by human antimurine antibody production Half Life: Not Available Dosage Forms of ProstaScint (Cytogen Corp): Not Available Chemical IUPAC Name: Murine anti-7E11 antibody Chemical Formula: Not Available Capromab on Wikipedia: https://en.wikipedia.org/wiki/Capromab Organisms Affected: Humans and other mammals